Application of G-CSF in AML is controversial as leukemic blasts may express receptors interacting with the cytokine, which may stimulate leukemia growth. We retrospectively analyzed the impact of G-CSF use to accelerate neutrophil recovery after auto-SCT on outcome. Adults with AML in first CR autografted between 1994 and 2010 were included. Nine hundred and seventy two patients were treated with G-CSF after auto-SCT whereas 1121 were not. BM and PB were used as a source of stem cells in 454 (22%) and 1639 (78%) cases, respectively. The incidence of relapse at 5 years in the BM-auto-SCT group was 38% for patients receiving post-transplant G-CSF and 43% for those not treated with G-CSF, P = 0.46. In the PB-auto-SCT cohort, respective probabilities were 48% and 49%, P = 0.49. No impact of the use of G-CSF could be demonstrated with respect to the probability of leukemia-free survival: in the BM-auto-SCT group, 51% for G-CSF(+) and 48% for G-CSF(− ), P = 0.73; in PB-auto-SCT group, 42% for G-CSF(+) and 43% for G-CSF( − ), P = 0.83. Although G-CSF administration significantly shortened the neutropenic phase, no beneficial effect was observed with regard to non-relapse mortality. In patients with AML, the use of G-CSF after auto-SCT is not associated with increased risk of relapse irrespective of the source of stem cells used.
INTRODUCTION G-CSF is widely used to accelerate neutrophil recovery after auto-SCT with the aim of reducing the risk of infectious complications, requirement for supportive care and duration of hospital stay. 1 Auto-SCT is an option for consolidating remission in a subgroup of patients with AML. It is offered especially to individuals achieving first CR (CR1), with good or intermediate cytogenetic and molecular risk features, and those lacking an allogeneic stem cell donor. 2, 3 Although a significant decrease in auto-SCT has been reported after the year 2000, this treatment modality continues to be used by some centers. According to data from the European Group for Blood and Marrow Transplantation (EBMT), auto-SCT now represents about 15-20% of transplants performed in AML. 4 The major disadvantage of auto-SCT is the risk of graft contamination with leukemic blasts and the lack of GVL effect. Hence, relapse of the disease occurring mainly within the first 2 years is a major cause of treatment failure. It was shown that leukemic clones surviving high-dose chemo-and/or radiotherapy or infused with contaminated transplant material contribute to AML recurrence. 5, 6 Application of G-CSF in AML is controversial as leukemic blasts may express G-CSF receptors interacting with the cytokine. 7, 8 Hence, there may be some concern about increased risk of relapse and reduced leukemia-free survival (LFS) when using G-CSF after auto-SCT in patients with AML. The goal of our study was to assess the impact of the use of G-CSF after auto-SCT, based on a retrospective analysis of a large cohort of patients reported to the EBMT registry.
SUBJECTS AND METHODS

Study design and data retrieval
This study was a retrospective multicenter analysis. Data were obtained from the EBMT registry. The registry maintains data reported by more than 500 participating transplant centers, including all consecutive stem cell transplantations and follow-ups updated once a year. The process of submitting data consists of mandatory filling minimum essential data (MED-A). Audits are routinely performed to determine the accuracy of the stored data. The study was approved by the Acute Leukemia Working Party of the EBMT, and followed EBMT registry study guidelines.
Criteria of selection
Adults with AML (excluding acute promyelocytic leukemia) treated with auto-SCT in CR1 between January 1994 and December 2010 were included in the analysis. Information regarding use of G-CSF in the immediate posttransplant period to hasten neutrophil recovery, which is documented in research forms (MED-B), was mandatory. Patients who received growth factors for engraftment failure were excluded from analysis.
Patients and auto-SCT procedure Two thousand and ninety-three auto-SCT procedures fulfiling search criteria were registered in the EBMT database. Among the population of 2093 patients, 972 were treated with G-CSF after auto-SCT whereas 1121 patients did not receive cytokines to support neutrophil recovery. BM and PB were used as the source of stem cells in 454 (22%) and 1639 (78%) cases, respectively. Within the BM-auto-SCT group, clinical characteristics were comparable, except for less common use of TBI as a preparative regimen in patients who received G-CSF support after auto-SCT (32 vs 44%, P = 0.007). The same trend could be noted in PB-auto-SCT group, TBI was used in 11% of patients who received G-CSF and in 16% of those who did not receive G-CSF after transplantation (P = 0.002). Among PB-auto-SCT, patients in the G-CSF subgroup had also statistically significant longer interval between diagnosis and CR1 (42 vs 39 days, P = 0.04) and a higher percentage of them had received more than one course of induction chemotherapy to achieve CR1 (17 vs 13%, P = 0.009). This may reflect a worse AML risk profile in this subgroup. There were no differences in all the subgroups regarding the distribution of French-American-British classification subtypes (data not shown). Table 1 summarizes patients' characteristics according to stem cell source.
Statistical analysis
The incidence of relapse (RI) was the primary study end point. Other points of interest were neutrophil engraftment rate and risk of primary graft failure, probability of LFS and non-relapse mortality (NRM).
LFS was defined as survival with no evidence of relapse. NRM was defined as probability of death while in CR. Cumulative incidence functions were used to estimate RI and NRM in a competing risks setting, as death and relapse are competing together. 9 Probabilities of LFS were calculated using the Kaplan-Meier estimate. Univariate analyses were done using logrank test for LFS, Gray's test for CIF. Multivariate analyses were performed using Cox proportional hazard model for LFS, Fine-Gray model for RI and NRM. 10 Patient-, disease-and transplant-related variables of the two groups (receiving G-CSF or not) were compared using χ 2 or Fischer's exact test for categorical variables and Mann-Whitney test for continuous variables. Factors differing between two groups in terms of distribution and all factors known to be potentially associated with the outcome were included in the final model. All tests were two-sided with type I error rate fixed at 0.05.
Engraftment was defined as achieving granulocyte recovery in PB higher than 500 cells/μL for 3 consecutive days, while primary graft failure occurred when these criteria were never met.
Separate analyses were performed for BM and PB groups because of different kinetics of engraftment and potentially different risk of relapse.
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Statistical analyses were performed with SPSS 19 (SPSS Inc, Chicago, IL, USA), and R 2.13.2 (R Development Core Team, Vienna, Austria) software packages.
RESULTS
Relapse incidence
No impact of the use of G-CSF could be demonstrated with respect to the RI. In the BM-auto-SCT setting, with the median follow-up of 64 months (range, 1-201) for patients treated with G-CSF and 102 months (2-214) for those not receiving G-CSF prophylaxis, the RI at 5 years was 38% (95% CI 31-44) and 43% (37-49), respectively (P = 0.46). In the PB-auto-SCT cohort, the respective median follow-up was 60 and 71 , and the RI rates were 48% (44-52) and 49% (46-53), P = 0.49 ( Figure 1) .
Administration of growth factor had also no impact on RI, irrespective of the conditioning regimen used. In the BMauto-SCT and TBI preparative regimen, RI reached 35% (23-48) for G-CSF(+) and 40% (31-49) for G-CSF( − ), P = 0.59. In the chemotherapy subgroup, RI was 38% (30-47) and 46% (37-54), P = 0.43, respectively. Patients transplanted with PB and conditioned with TBI had RI of 41% (30-51) for G-CSF(+) and 54% (45-62) for G-CSF( − ), P = 0.14. For those treated with chemotherapy, corresponding figures were 49% (45-53) and 48% (45-52), P = 0.93.
Older age and more than one induction course needed to achieve CR were factors that independently were associated with higher RI both in BM-and PB-auto-SCT groups. Favorable karyotype was predictive of lower RI within PB-auto-SCT group (Table 2) .
Hematopoietic reconstitution
In the overall population, 94% patients met the criteria of neutrophil engraftment after BM-auto-SCT and 98% after PB-auto-SCT. The rate of graft failure in the BM-auto-SCT Table 1 . Patient and transplant characteristics according to the use of G-CSF Impact of G-CSF use after auto-SCT on AML relapse T Czerw et al setting was comparable for patients receiving G-CSF prophylaxis and those not treated with G-CSF (7 vs 5%, P = 0.33). Also, no difference could be demonstrated for the risk of graft failure in the PB-auto-SCT cohort (2% irrespective of the use of G-CSF, P = 0.77). Among BM-auto-SCT recipients, the use of G-CSF was associated with significantly faster neutrophil recovery (median 29 vs 32 days, P = 0.02). The same could be observed in the PB-auto-SCT cohort (median 12 vs 14 days, Po 0.001). The probability of reaching platelet counts of >20 ×10 9 /L 6 months after BM-auto-SCT did not differ between patients receiving G-CSF or not (80% (67-88) vs 72% (59-82), P = 0.51). Such difference was also not seen in PB-auto-SCT group (94% (91-95) vs 93% (90-95), P = 0.12).
Leukemia-free survival The probabilities of LFS 5 years after BM-auto-SCT were 51% (43-58) for patients who received G-CSF after transplantation and 48% (42-55) for those who did not receive G-CSF support, P = 0.73. In PB-auto-SCT group, corresponding values were 42% (38-46) for G-CSF(+) and 43% (40-47) for G-CSF(− ), P = 0.83.
Older age, above the median of 48 years (hazard ratio (HR) 1.61, 95% CI 1.22-2.12, P = 0.0006 for BM-auto-SCT; HR 1.47, 95% CI 1.27-1.69, P o0.0001 for PB-auto-SCT), and more than one induction course needed to achieve CR (HR 1.7, 95% CI 1.21-2.39, P = 0.002 for BM-auto-SCT; HR 1.41, 95% CI 1.17-1.69, P = 0.0003 for PB-auto-SCT) were independently associated with worse LFS both in BM-and PB-auto-SCT groups. Favorable karyotype was predictive of better LFS within PB-auto-SCT group (HR 0.43, 95% CI 0.31-0.6, P o0.0001).
Non-relapse mortality No significant effect was observed for NRM. In the BM-auto-SCT group, NRM was calculated as 12% (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) for G-CSF(+) and 8% (5-12) for G-CSF( − ), P = 0.12. In the PB-auto-SCT group, 9% (7-11) for G-CSF(+) and 7% (5-9) for G-CSF( − ), P = 0.26.
In a multivariate analysis, year of transplantation (after median 2001) was found to be independently associated with a lower probability of NRM among patients transplanted with BM as a stem cell source (HR 0.48, 95% CI 0.26-0.91, P = 0.02). In the PBauto-SCT cohort, older age was the only factor that significantly affected higher NRM (HR 2.47, 95% CI 1.67-3.65, P o 0.0001).
DISCUSSION
Myeloid blasts express receptors for hematopoietic growth factors, and may exhibit variable responses when being exposed to them. This includes either malignant clone proliferation or granulocytic maturation. 7, 8, 12 In the current study, we have addressed the issue of the potential impact of the use of G-CSF early after auto-SCT to accelerate hematopoietic recovery on the probability of AML recurrence. To the best of our knowledge this is the first study focusing on this issue taking into account a large, homogenous population of autografted patients. In all, we could not demonstrate an impact of the G-CSF prophylaxis on the RI. This held true for both BM and PB used as a source of stem cells. Moreover, the effect could not be shown when patients treated with chemotherapy and TBI-based conditioning were analyzed separately. The potential limitation of these findings is that precise determination of the reasons to use G-CSF after auto-SCT by the Abbreviations: CI = confidence interval; HR = hazard ratio; RI = relapse incidence. Statistically significant values are indicated in bold.
Impact of G-CSF use after auto-SCT on AML relapse T Czerw et al centers (per protocol or due to anticipated poor engraftment) was impossible. Important changes in diagnostic tools, which have been incorporated in the clinic over a 17-year period of accrual, especially the possibility of detecting minimal residual disease before auto-SCT, represent the other factors that could have influenced the results. For this reason we performed additional sub-cohort analyses dividing study populations according to the median year of transplantation (1996 for BM-auto-SCT and 2001 for PB-auto-SCT group). Once again, we did not find any adverse effect of G-CSF use on RI (data not shown). Thus far, in the only publication related to the use of G-CSF after auto-SCT in AML, Majhail et al. included in the analysis patients who had survived in continuous CR for at least 2 years after transplantation. 13 In this retrospective study, the use of growth factors to hasten neutrophil recovery was found to be the only factor associated with an increased risk of late relapses (HR 3.64, P = 0.013). However, as most AML relapses occur during the first 2 years after auto-SCT, this finding might have resulted from a selection bias, which was also stated by the authors.
Our data correspond to previous observations on the use of G-CSF to support initial chemotherapy of AML.
14-20 G-CSF prophylaxis during and following induction and consolidation was not shown to adversely affect the CR rate, the RI or the LFS in meta-analysis of 19 randomized trials. 21 On the other hand, however, there are also recent data indicating that under particular circumstances G-CSF may stimulate leukemogenesis in AML. AML-BFM 98 study (patients younger than 18 years) reported a trend toward increased RI in the standard-risk patients assigned to receive prophylactic G-CSF after initial therapy. 22 Furthermore, overexpression of differentiation-defective G-CSF receptor isoform IV on blast clones was found to be a significant and pivotal risk factor for relapse among patients receiving G-CSF (5-year RI 50 vs 14% in patients with low-level expression, P = 0.04). In patients not receiving G-CSF, the level of expression of this molecule had no influence on RI. 23 It was previously shown that AML cell lines and AML patient samples express increased relative amounts of the class IV isoform G-CSF receptor. 24, 25 These data suggest that despite the lack of evidence for an increased risk of relapse associated with G-CSF administration in general, there may be particular AML patient subsets susceptible to this effect. In our study, the number of cases with standard-risk AML was relatively small, so we were able to analyze it separately only in the PB-auto-SCT group. However, once again, the potential adverse role of G-CSF use was not observed (data not shown). It may be hypothesized that the potential negative effect of G-CSF in de novo AML may not necessarily be relevant among patients referred for auto-SCT, who are in first CR with a low tumor burden.
As expected, in the current analysis the use of G-CSF significantly shortened the duration of the neutropenic phase after transplantation both in BM-and PB-auto-SCT groups (by median 3 and 2 days, respectively). The differences, however, were relatively small and clinically unimportant, as the incidences of graft failure and NRM were comparable. These findings are consistent with previously published data in lymphoid malignancies and solid tumors. [26] [27] [28] In the meta-analysis of randomized controlled trials, the prophylactic use of growth factors after auto-SCT was associated with faster neutrophil recovery, reduction of days of parenteral antibiotics and hospital stay. 29 These benefits, however, did not translate into a reduction of NRM.
In conclusion, our results indicate that in the general population of patients with AML, the use of G-CSF after auto-SCT is not associated with an increased risk of relapse and may be considered safe, irrespective of the source of stem cells used for transplantation. However, on the basis of the recent findings, individual susceptibility related to the biology of leukemic blasts cannot be excluded. Future investigations should focus on particular genetic subtypes and optimally take into account the expression of G-CSF receptors and their isoforms.
